Beta Drugs Ltd Q4 FY2024 Concall Summary

Key Takeaways

• Broad-based growth, margin squeeze from platins: Own-brand sales rose 27%, CDMO added clients, and API grew 30%, but gross margin fell 4 pp to 49% as platins (16-17% of sales) saw input price spikes.
• Cosmetology is the next leg, now live: The Inspira division launched PAN-India with 100+ reps covering 6,800 doctors, targeting Rs. 14+ crore in FY25 sales from a doctor-prescribed, hair-care-focused ethical model.
• Regulatory unlocks are stacking up: Eurasia audit cleared, 53 export registrations received, EU GMP audit set for September, and Mainboard migration targeted within 2-3 months.
• Cytotoxic suspension facility is a first-mover asset: Billed as the first such facility in Asia, Africa, and Europe, it has already launched megestrol acetate suspension domestically, with 6 more approvals filed.
• What to watch next quarter: The pace of cosmetology sales build toward the Rs. 14 crore target, the EU GMP audit outcome in September, and whether platin prices continue their recent decline to ease the margin headwind.

Cosmetology: The Second Growth Engine

• Model mirrors oncology: Cosmetology is a doctor-prescribed, ethical business where the doctor is the sole customer, products move from stockist to patient, and brand is built through physician recommendation.
• Hair-care focus: Management chose hair care over beauty because it is a segment few companies have focused on in India, and they believe their oncology brand-building playbook transfers directly.
• Early traction: The Inspira division achieved Rs. 1 crore in sales in April as a minimum benchmark, with a field force of over 100 people now covering 6,800 doctors PAN-India.
• Product ramp underway: 5 products recently launched (hair care, psoriasis, skin brightening), with SKU count planned to rise from 14 to 30-35 by FY25-end.
• Manufacturing independence: An own cosmetology plant is planned by FY26, with CAPEX close to Rs. 30-35 crores, removing third-party dependency as the business scales.
• Margin profile: Management expects cosmetology margins to be at the same line as oncology, and at a Rs. 450-500 crore top line, cosmetology will contribute a substantial figure within 4-5 years.

Rahul Batra: "Last year was a bit of learning and hiring year. As you all are aware that a brand can be created if you have the right team and at the right place along with the great direction."

Oncology & Core Formulations

• Own-brand momentum: Sales increased 27%, driven by 7 new product launches, and the injectable-to-oral mix shifted from 61:39 to 43:57 as management deliberately tilts toward the stickier oral prescription business.
• Cytotoxic suspension facility: Billed as the first ever in Asia, Africa, and Europe, it launched megestrol acetate suspension in the domestic market, gained market share, and expanded the market size for the product.
• Oncology market dynamics: When an innovator drug goes off-patent, the market size shrinks to roughly one-eighth, but Beta is often the only manufacturer and first to launch, capturing maximum market share with 80-85% gross margins in own brands.
• Hematology build-out: Two more products were added to the hematologic portfolio, and management sees the segment's scope and future as a continued focus area.
• Capacity headroom: Existing oncology capacity can support sales up to Rs. 500 crores with no further expansion needed.

Rahul Batra: "This is the first ever facility in Asia, Africa, Europe."

Exports & Regulatory Catalysts

• Eurasia audit cleared: One of the toughest audits after ANVISA, covering Russia, Armenia, Belarus, Georgia, and Kazakhstan, now cleared with a registration certificate received.
• 53 new registrations received: Export business from these registrations has already started flowing and will be in free flow for the coming year, with 350-plus registrations still in the pipeline for the next two years.
• Latin America filings: 10-12 dossiers filed in Colombia, around 24 in Mexico, around 6 in Brazil, with registrations already received in Peru, Guatemala, Ecuador, and Nicaragua.
• EU GMP audit in September: Confirmed for September; once approved, management plans to immediately acquire Marketing Authorizations to launch products in a shorter time, bypassing the 3-4 year registration process.
• US market entry sequenced last: Management is not in a hurry; the plan is to establish in Southeast Asia, then Latin America, then Europe, with US entry targeted 3 years down the line.

Rahul Batra: "This was one of the toughest audits we faced after ANVISA. We are proud to say that we have cleared the audit and we have got our registration certificate from Eurasia."

CDMO & API: The Other Growth Legs

• CDMO growth: Added 3 new clients, while existing clients added 7-8 new products; management expects continued growth and further client additions.
• API business grew 30%: Seven new API products were developed and launched last year, and a small amount of exports has started.
• API quality focus: Management is focused on quality aspects to bring the API business to par with the formulation business.
• Platin margin drag: Platins constitute 16-17% of total sales and are sourced externally (Hetero Healthcare, Fresenius Kabi); price increases compressed gross margin by 4 pp, but prices have declined over the last 3 months.
• Below-OPEX discipline: Despite the gross margin hit, EBITDA margin declined only 2.4 pp (25% to 22.6%) because expenses below gross margin were controlled by around 1 pp.

People, Infrastructure & Corporate Actions

• Mainboard migration: Process already initiated; management expects to migrate to the Mainboard within the next 2-3 months (June or July 2024).
• Tier-2 and Tier-3 expansion: People were recruited in the last quarter of FY24 for headquarters like Mangalore, Coimbatore, and Raipur, and sales generation has already started from those locations.
• R&D strengthening: The R&D department has been centered by hiring more professionals and competent people.
• New product development: Two products that will be first-time launches in the Indian market have been developed, with one more under development; total approval timeline is 12-18 months.
• Biosimilar JV stance: Not actively looking but not passive either; management has spoken to certain parties and will consider an opportunity if a good biotech facility seeks investment or a partner to launch a biosimilar in India.

Rahul Batra: "We are not looking actively, but it's not passive also. So, we have spoken to certain people in case any opportunity comes. So, we don't mind considering that opportunity."

Guidance & Commitments

Key Metrics